Similar articles

• Correlation of molecular conformation and activity of reverse transcriptase inhibitors.

  Van Roey P, Taylor EW, Chu CK, Schinazi RF. Van Roey P, et al. Ann N Y Acad Sci. 1990;616:29-40. doi: 10.1111/j.1749-6632.1990.tb17825.x. Ann N Y Acad Sci. 1990. PMID: 1706572 Review. No abstract available.
• [HEPT and its related compounds as anti-HIV agents].

  Miyasaka T, Tanaka H, Baba M. Miyasaka T, et al. Nihon Rinsho. 1993 Sep;51 Suppl:200-6. Nihon Rinsho. 1993. PMID: 7505847 Review. Japanese. No abstract available.
• Identification of a pharmacophore for nucleoside analog inhibitors directed at HIV-1 reverse transcriptase.

  Fisher MA, Yadav PN, Yadav J, Kristol D, Arnold E, Modak MJ. Fisher MA, et al. J Mol Recognit. 1994 Sep;7(3):211-4. doi: 10.1002/jmr.300070309. J Mol Recognit. 1994. PMID: 7533506
• Nucleoside spiroxiranes as suicide inhibitors of the human immunodeficiency virus.

  Bailey JM, Nelson KA. Bailey JM, et al. Biochem Soc Trans. 1995 Nov;23(4):619S. doi: 10.1042/bst023619s. Biochem Soc Trans. 1995. PMID: 8654804 No abstract available.
• All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.

  Gussio R, Pattabiraman N, Zaharevitz DW, Kellogg GE, Topol IA, Rice WG, Schaeffer CA, Erickson JW, Burt SK. Gussio R, et al. J Med Chem. 1996 Apr 12;39(8):1645-50. doi: 10.1021/jm9508088. J Med Chem. 1996. PMID: 8648604